Israeli pharmaceutical company Panaxia Pharmaceuticals Industries Ltd, specializing in medical cannabis R&D and manufacturing, and Ultra Health, New Mexico’s No. 1 cannabis company with a nationwide presence, launched their first medical cannabis production facility in the United States.
Based in Bernalillo, New Mexico, the facility will manufacture smokeless, accurately dosed cannabis medicine in a variety of delivery methods.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Although Panaxia pharmaceutical Industries produces more than 300 different conventional medication products, the company has been developing and manufacturing medical products based on cannabis since 2010.
Panaxia is providing smokeless proprietary cannabinoid dosage and treatment protocols, which are not readily available in the United States, in order to manufacture state-of-the-art products to treat a number of illnesses. The production facility is implementing Panaxia’s technology.
Bernalillo, New Mexico mayor, launches Panaxia medical cannabis facility in the US
The smokeless products include sublingual and oral tablets, rectal and vaginal suppositories, cannabis oil, pastilles, transdermal pain relief patches and topical creams for the treatment of pain, burns and psoriasis. They are beneficial to current chronic conditions requiring ongoing dosing such as PTSD, chronic pain, cancer, neuropathy pain, epilepsy, anorexia and HIV/AIDS.
“The new 18 smokeless-designed cannabis products are providing better delivery systems for patients and physicians by delivery of a fully potent, targeted dosage specifically tailored to the patient’s needs,” said Duke Rodriguez, CEO and President of Ultra Health. “Patients will also have the opportunity to purchase products containing only Tetrahydrocannabinol (THC), products containing only Cannabidiol, (CBD) as well as products with an equal THC and Cannabidiol (CBD) ratio.”
Dr. Dadi Segal, CEO of Panaxia said “It is history in the making for an Israeli company to bring the tidings to the citizens of New Mexico. Panaxia is part of an organization that has been active in the Israeli and global pharmaceutical industry for more than 40 years.”
